The Primary Isolation and Specimen Banking Core (PISBC) will be responsible for the primary isolation, quantitation, and storage of clinical specimens and HIV isolates obtained from infected persons. Specific functions to be performed by the PISBC will include: (1) Primary isolation of HIV by peripheral blood mononuclear cell (PBMC) culture of specimens of interest including PBMC, plasma, macrophages, cerebrospinal fluid (CSF), tissue specimens, etc. (2) Quantitation of infectious virus load as determined by quantitative culture of PBMC, plasma, CSF and other specimens as required; and (3) Storage of clinical specimens and virus isolates for future use by interested investigators. Specimens and HIV isolates obtained by the PISBC will be labelled, stored at 80 C or in liquid nitrogen (when required), and entered into a computerized data base for easy retrieval. In cooperation with Biostatistical Core, additional information regarding the source of each specimen, clinical data including disease status, CD4+ lymphocyte count, treatment, etc. will be incorporated into the data base. To optimize clinical data retrieval, all specimens obtained from persons participating in the major clinical HIV programs at UCSD including the Adult AIDS Clinical Trails Unit (ACTU), the Pediatric ACTU, the California Collaborative Treatment Group (CCTG), and the HIV Neurobehavioral Research Center will have their data bases cross-linked with the PISBC. Thus, the PISBC will serve to optimize the utilization of well-characterized clinical specimens by making them available to the wider community of investigators within the UCSD CFAR.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
5P30AI036214-03
Application #
5205747
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
3
Fiscal Year
1996
Total Cost
Indirect Cost
Chaillon, Antoine; Gianella, Sara; Lada, Steven M et al. (2018) Size, Composition, and Evolution of HIV DNA Populations during Early Antiretroviral Therapy and Intensification with Maraviroc. J Virol 92:
Bengtson, Angela M; Pence, Brian W; Eaton, Ellen F et al. (2018) Patterns of efavirenz use as first-line antiretroviral therapy in the United States: 1999-2015. Antivir Ther 23:363-372
Dubé, Karine; Gianella, Sara; Concha-Garcia, Susan et al. (2018) Ethical considerations for HIV cure-related research at the end of life. BMC Med Ethics 19:83
Mittal, María Luisa; Bazzi, Angela Robertson; Rangel, María Gudelia et al. (2018) 'He's not my pimp': toward an understanding of intimate male partner involvement in female sex work at the Mexico-US border. Cult Health Sex 20:961-975
Letendre, Scott; Bharti, Ajay; Perez-Valero, Ignacio et al. (2018) Higher Anti-Cytomegalovirus Immunoglobulin G Concentrations Are Associated With Worse Neurocognitive Performance During Suppressive Antiretroviral Therapy. Clin Infect Dis 67:770-777
Basova, Liana; Najera, Julia A; Bortell, Nikki et al. (2018) Dopamine and its receptors play a role in the modulation of CCR5 expression in innate immune cells following exposure to Methamphetamine: Implications to HIV infection. PLoS One 13:e0199861
Eren, Kemal; Murrell, Ben (2018) RIFRAF: a frame-resolving consensus algorithm. Bioinformatics 34:3817-3824
de Almeida, Sérgio Monteiro; Ribeiro, Clea E; Rotta, Indianara et al. (2018) Biomarkers of neuronal injury and amyloid metabolism in the cerebrospinal fluid of patients infected with HIV-1 subtypes B and C. J Neurovirol 24:28-40
Martin, Thomas C S; Rauch, Andri; Salazar-Vizcaya, Luisa et al. (2018) Understanding and Addressing Hepatitis C Virus Reinfection Among Men Who Have Sex with Men. Infect Dis Clin North Am 32:395-405
Jenks, Jeffrey D; Hoenigl, Martin (2018) Treatment of Aspergillosis. J Fungi (Basel) 4:

Showing the most recent 10 out of 921 publications